VolitionRx Limited (VNRX) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
VolitionRx Limited is a multi-national epigenetics company developing blood tests for early detection of cancer and sepsis using nucleosome biomarkers. The company operates in a pre-profitability stage, transitioning from research and development to commercialization. This report covers the nine months ended September 30, 2025. The company is classified as a smaller reporting company and a non-accelerated filer.
Key Financial Metrics
| Metric | Nine Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2024 |
|---|---|---|
| Total Revenues | $1,280,350 | $1,041,854 |
| Net Loss | $(17,200,488) | $(21,400,758) |
| Operating Loss | $(16,920,187) | $(21,243,630) |
| Cash and Cash Equivalents (End of Period) | $199,407 | $5,414,146 |
| Net Cash Used in Operating Activities | $(14,191,467) | $(20,461,849) |
| Total Debt (Current + Long-Term) | $6,479,333 (Long-term) + $913,582 (Current) | $3,952,846 (Long-term) + $860,223 (Current) |
| Convertible Note Payable (Net) | $3,787,797 | $0 |
| Accumulated Deficit | $(246,630,538) | $(229,544,343) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23% year-over-year, driven primarily by a 135% increase in service revenue ($366k vs $156k) from Nu.Q Discover services, while product revenue grew modestly by 3%.
- Expense Reduction: Total operating expenses decreased 18% to $18.2 million. Research and Development (R&D) expenses dropped 36% to $7.6 million due to reduced clinical trial activity and personnel costs. Sales and marketing expenses fell 29% to $2.9 million.
- Increased G&A: General and Administrative expenses rose 21% to $7.7 million, attributed to higher legal fees and stock-based compensation.
- Debt Financing: The company issued a $7.5 million senior secured convertible note in May 2025, resulting in significant non-cash interest expense (amortization of debt discount) of $1.05 million for the period.
- Cash Position: Cash reserves declined significantly from $3.26 million at year-end 2024 to $0.2 million at September 30, 2025, despite raising approximately $11 million in financing activities.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern beyond one year from the report date due to recurring losses and negative cash flows. Continued operations depend on securing additional financing.
- Financing Activity: The company raised capital through multiple channels in 2025, including a $7.5M convertible note, registered direct offerings (March, August), private placements (September), and "at-the-market" offerings. A subsequent underwritten offering closed in October 2025 raising approximately $5.4 million.
- Unusual Items: The income statement includes a $723k gain on the change in fair value of a derivative liability (non-cash) related to the convertible note, partially offsetting the $1.05M amortization of debt discount.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting due to insufficient written documentation of policies and procedures. Remediation plans are underway.
- Strategic Partnerships: New agreements were signed in September 2025 with Werfen (Antiphospholipid Syndrome) and Hologic Diagenode (co-marketing Nu.Q Discover).
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $0.2 million cash balance against the $3.0 million in contractual payments due in the remainder of 2025 and the $14.6 million due in 2026-2029.
- Debt Covenants: Review the terms of the $7.5 million Lind convertible note, specifically the default penalties (120% of principal) and conversion mechanics tied to stock price volatility.
- Revenue Sustainability: Assess the durability of the service revenue growth from Nu.Q Discover and the commercialization progress of the Nu.Q Vet Cancer Test with partners like Heska and IDEXX.
- Dilution Risk: Monitor the impact of the October 2025 underwritten offering and the outstanding 48 million warrants and options on future share count.
- Internal Control Remediation: Track the progress of the plan to centralize accounting functions and document internal controls to address the material weakness.